Childhood Cancer Research


Too many types of childhood cancer still have no known cure or treatment. In 2018, more than 15,000 children under age 19 will be diagnosed with cancer. 

We must ensure that researchers have the essential tools to fight childhood cancer and make sure children with cancer not only survive, but thrive. 


Over 15,000 U.S. children under age 19 will be diagnosed with cancer in 2018.

Take Action

children celebrating

Congress: Fund The STAR Act To Help Prevent And Treat Childhood Cancer

Ask your member of Congress to ensure the STAR Act is fully funded so vital work on childhood cancer research, surveillance, and survivorship can continue. 

Latest Updates

March 11, 2019

The administration released its FY20 budget today including a $4.7 billion cut for medical research at the National Institutes of Health (NIH) including a nearly $900 million cut for the National Cancer Institute (NCI).

September 20, 2018

The American Cancer Society Cancer Action Network hosted its fourth annual Cancer Research Breakfast this morning at the Inova Center for Personalized Health Conference Center. The event featured cancer researchers from five of Virginia’s leading research institutions, discussing the latest breakthroughs in the battle against cancer.

Cancer Candor Blog
August 31, 2018

ACS CAN is once again joining patients, families, caretakers and other public health advocacy organizations in recognizing September as Childhood Cancer Awareness Month.

June 28, 2018

The Senate Appropriations Committee approved its FY 2019 Labor, Health and Human Services spending bill today. The bill includes a $2 billion funding increase for the National Institutes of Health (NIH) and a $190 million funding boost for the National Cancer Institute (NCI).

Childhood Cancer Research Resources

ACS CAN’s official endorsement of the RACE for Children Act, a bill that will encourage new research and development in childhood cancer.

This report examines the drug development landscape for childhood cancer, identifying scientific, logistical, economic and ethical challenges that are unique to pediatric cancer drug development.